Credit Suisse Lowers Ariad Pharmaceuticals Price Target to $2.50 (ARIA)
Investment analysts at Credit Suisse decreased their target price on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from $4.00 to $2.50 in a note issued to investors on Friday, American Banking and Market News reports. The firm currently has a “neutral” rating on the stock. Credit Suisse’s target price would suggest a potential downside of 3.10% from the stock’s previous close.
A number of other firms have also recently commented on ARIA. Analysts at BMO Capital Markets cut their price target on shares of Ariad Pharmaceuticals from $8.00 to $2.50 in a research note to investors on Friday. Separately, analysts at Leerink Swann downgraded shares of Ariad Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note to investors on Friday. They now have a $2.50 price target on the stock, down previously from $7.00. Finally, analysts at Jefferies Group downgraded shares of Ariad Pharmaceuticals from a “buy” rating to a “hold” rating in a research note to investors on Friday. They now have a $2.50 price target on the stock, down previously from $7.00. Two research analysts have rated the stock with a sell rating, twenty have issued a hold rating and two have issued a buy rating to the company’s stock. Ariad Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $10.41.
Ariad Pharmaceuticals (NASDAQ:ARIA) opened at 2.58 on Friday. Ariad Pharmaceuticals has a 52 week low of $2.15 and a 52 week high of $25.40. The stock’s 50-day moving average is $11. and its 200-day moving average is $16.75. The company’s market cap is $477.6 million.
Ariad Pharmaceuticals (NASDAQ:ARIA) last released its earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.40) by $0.03. The company had revenue of $13.90 million for the quarter, compared to the consensus estimate of $11.11 million. During the same quarter last year, the company posted ($0.31) earnings per share. Ariad Pharmaceuticals’s revenue was up 4302.5% compared to the same quarter last year. On average, analysts predict that Ariad Pharmaceuticals will post $-1.62 earnings per share for the current fiscal year.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.